Preparation, biodistribution and scintigraphic evaluation of [99m]Tc-lincomycin

A complex of lincomycin was synthesized with technetium-99m. The synthesis was carried out by using SnCl[2].2H[2]O as reducing agent and ascorbic acid as stabilizer. The effect of various parameters such as amount of ligand/reducing agent, pH value and reaction time on radio labeling process was studied. The characterization of the [99m]Tc-Lincomycin was performed by HPLC and electrophoresis Biodistribution studies were carried out by analyzing the model of bacterial infectious rats [Sprague-Dawley]. The uptake of infectious lesions at different time interval was also studied by using scintigraphic technique. The complex showed effective target to non-target ratio for various inflammatory or infectious lesions. The [99m]Tc-Lincomycin effective binding to living bacteria and could be used successfully as an infection imaging agent

Evaluation of carrier added and no carrier added [90]Y-EDTMP as bone seeking therapeutic radiopharmaceutical

The optimum conditions to label ethylenediaminetetramethylene phosphonate [EDTMP] compound with [90]y as a potential candidate for bone metastases therapy were investigated. Yttrium-90 is a pure beta-emitter and can be obtained by 89y [n,gamma] [90]y nuclear reaction in a reactor or from an in-house generator system [[90]sr[rightwards arrow][90]y]. The preparation of [90]y-EDTMPis described using [90]y, which was obtained from neutron irradiation of y2o3 as well as from a laboratory scale organic resin-based [90]sr[rightwards arrow][90]y generator. Because of the radiolabeling yield of [90]y-EDTMP on ligand/metal molar ratio, incubation time and ph was evaluated. Under optimum parameters, the radiolabeling yields of [90]y-EDTMPwere <95% for no-carrier-added as well as carrier-added [90]y. The biodistribution of no-carrier-added and carrier-added [90]yEDTMPcomplexes in rats was identical. The results indicate that [90]y [carrier-added]-edtmp is also an effective bone pain palliation agent because of its rapid blood clearance, greater uptake in bones and little absorption in soft tissues

Pharmacokinetics for dose proportion; estimation of 250 mg cefaclor tablet in male volunteers

To estimate dose proportion for male volunteers by calculating pharmacokinetics following oral administration of Cefaclor [CCL] 250mg Tablet and to check the relative susceptibility of four bacterial strains. Randomized Clinical Trial, case series. Department of Chemistry and Biochemistry, University of Agriculture, Faisalabad. From Mar 2006 to Feb 2007. Blood samples were collected for the period of 12 hours in heparinized tubes. Collected samples were centrifuged at 3000xg and plasma thus separated was stored at -10°C until further analysis. The CCL plasma concentration was determined via bioassay using disc diffusion method. Pharmacokinetics parameters were calculated using American Pharmacology Organization [APO] computer software. Renal Clearance [CL], volume of distribution [VD], time of Peak [T[max]], maximum plasma concentration [C[max], mean residence time [MRT], absorption half life, elimination half life and the Area Under plasma Concentration [AUC [t0tot12h] showed that the four bacterial strains have different susceptibility against cefaclor and administration of cefaclor at rate of 250 mg as tablet orally thrice daily maintained considerable concentration [>MIC] that prove it to be very effective for the treatment of specific infections in male volunteers

Carcinoma Gall bladder with situs inversus totalls

We report a case of carcinoma gall bladder with situs inversus totalis in a 65 years old lady. She presented very late with obstructive jaundice and gastric outlet obstruction. Different imaging tests were done to accurately outline vital structures. At laparotomy the carcinoma was inoperable, hence a palliative percutaneous external biliary drainage and gastrojejunostomy was done. She survived for three months but ultimately died of disseminated cancer